Respiratory syncytial virus infections in infants affected by primary immunodeficiency.
Respiratory syncytial virus infections in infants affected by primary immunodeficiency.
复制标题
DOI：
10.1155/2014/850831
复制
发表时间：
2014
影响因子：
4.1
通讯作者：
Faldella G
中科院分区：
文献类型：
--
作者：
Lanari M;Vandini S;Capretti MG;Lazzarotto T;Faldella G
原发免疫缺陷是一种罕见的遗传性疾病，可能导致频繁且往往严重的急性呼吸道感染。呼吸道合胞病毒(RSV)是婴幼儿最常见的病原体之一，免疫低下婴儿的感染比健康婴儿更为严重，原因是T细胞和B细胞免疫反应受损，无法有效地中和病毒复制，从而增加病毒的脱落和潜在的致命性下呼吸道感染。几位作者报告了患有原发和获得性免疫缺陷的婴儿和儿童在感染RSV后出现严重的临床过程。为了减少住院免疫低下婴儿在流行季节的感染，环境预防是必不可少的。Palivizumab是一种人源化的抗RSV F蛋白的单抗，目前推荐用于早产、患有慢性肺部疾病或先天性心脏病的高危婴儿的预防。然而，尽管一些作者建议将预防措施扩展到这一高危人群，但目前并不常规地建议对患有原发免疫缺陷的婴儿进行预防。
Primary immunodeficiencies are rare inherited disorders that may lead to frequent and often severe acute respiratory infections. Respiratory syncytial virus (RSV) is one of the most frequent pathogens during early infancy and the infection is more severe in immunocompromised infants than in healthy infants, as a result of impaired T- and B-cell immune response unable to efficaciously neutralize viral replication, with subsequent increased viral shedding and potentially lethal lower respiratory tract infection. Several authors have reported a severe clinical course after RSV infections in infants and children with primary and acquired immunodeficiencies. Environmental prophylaxis is essential in order to reduce the infection during the epidemic season in hospitalized immunocompromised infants. Prophylaxis with palivizumab, a humanized monoclonal antibody against the RSV F protein, is currently recommended in high-risk infants born prematurely, with chronic lung disease or congenital heart disease. Currently however the prophylaxis is not routinely recommended in infants with primary immunodeficiency, although some authors propose the extension of prophylaxis to this high risk population.
登录
查看更多内容
DOI：
10.4049/jimmunol.1000423
发表时间：
2010-08-15
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Fulton RB;Meyerholz DK;Varga SM
通讯作者：
Varga SM
DOI：
10.1056/nejmoa0804877
发表时间：
2009-02-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Hall CB;Weinberg GA;Iwane MK;Blumkin AK;Edwards KM;Staat MA;Auinger P;Griffin MR;Poehling KA;Erdman D;Grijalva CG;Zhu Y;Szilagyi P
通讯作者：
Szilagyi P
影响因子：
158.5
作者：
HALL, CB;POWELL, KR;COHEN, HJ
通讯作者：
COHEN, HJ
影响因子：
4.5
作者：
Choi JH;Choi EH;Kang HJ;Park KD;Park SS;Shin HY;Lee HJ;Ahn HS
通讯作者：
Ahn HS
影响因子：
14.2
作者：
Baker, Mei W.;Grossman, William J.;Routes, John M.
通讯作者：
Routes, John M.